{"schema_version":"secwatch.filing_event.v1","accession":"0000313616-26-000163","form_type":"8-K","ticker":"DHR","cik":"0000313616","company_name":"DANAHER CORP /DE/","filed_at":"2026-07-20T21:55:01+00:00","discovered_at":"2026-07-21T10:05:00.249686+00:00","generated_at":"2026-07-21T10:05:56.300128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Danaher Q2 2026 EPS $1.23 (up 60% YoY), raises full-year adjusted EPS guidance to $8.45-$8.60","bullets":["Net earnings $870M ($1.23 diluted EPS) up 60% YoY; adjusted EPS $1.94 up 8.0%.","Revenue $6.3B (+5.5% YoY); core revenue +3.0% (+4.5% ex-respiratory testing).","Operating cash flow $1.5B, free cash flow $1.3B.","Full-year 2026 adjusted EPS guidance raised to $8.45-$8.60 from $8.35-$8.55.","Bioprocessing orders grew mid-teens; Life Sciences had strongest quarter in years."],"urls":{"canonical":"https://secwatch.observer/filing/0000313616-26-000163","json":"https://secwatch.observer/filing/0000313616-26-000163.json","markdown":"https://secwatch.observer/filing/0000313616-26-000163.md","text":"https://secwatch.observer/filing/0000313616-26-000163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000163/0000313616-26-000163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/313616/000031361626000163/dhr-20260721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-21T10:05:56.300128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}